Clinical trials: Inhalation
Pulmonary Disease, Chronic Obstructive
Effect of GSK704838 In Healthy Volunteers
GSK704838C is a potent, pan-active mAChR antagonist, which is being developed for once-daily treatment of chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00539825
- Testing
- GSK704838
- Where
- United Kingdom
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects
This is a double-blind, single dose (four inhalations), four-way cross over study in healthy subjects that will assess the systemic pharmacokinetics (PK) and systemic pharmacodynamics (PD) of Fluticasone Furoate, (FF)…
- Trial name
- NCT01691547
- Testing
- UMEC /VI, UMEC, VI
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
A Drug Interaction Study With Fluticasone Furoate/GW642444 Inhalation Powder and Ketoconazole
A randomized two-way crossover study to determine whether concomitant administration of CYP P450 3A4 inhibitor ketoconazole and fluticasone furoate/GW642444M combination significantly increases the systemic effects and exposure…
- Trial name
- NCT01165125
- Testing
- FF / GW642444, ketoconazole
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Central Sleep Apnea (Diagnosis), Central Sleep Apnea Syndrome
Registry of Central Sleep Apnea Patients Undergoing remedē System Implant
The goal of this observational study is to collect information on the safety and performance of the remedē System in patients with central sleep apnea who are undergoing the remedē System implant procedure.
- Conditions
- Central Sleep Apnea (Diagnosis), Central Sleep Apnea Syndrome, Central Sleep Apnea, Phrenic Nerve Stimulation
- Trial name
- ROSTER (NCT07907068)
- Testing
- Phrenic nerve stimulation
- Volunteers
- 300 people
- Sponsor
- Zoll Medical Corporation
Asthma
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I
The aim of this trial is to evaluate the efficacy and safety of 2.5 and 5 mcg tiotropium over a 24-week treatment period as compared to placebo and salmeterol (50 mcg twice daily).
- Trial name
- NCT01172808
- Testing
- tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI
- Where
- 114 sites in United States, Brazil and 9 more
- Volunteers
- 1,071 people
- Sponsor
- Boehringer Ingelheim
Cystic Fibrosis
Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) - Extension Phase
A major factor in the respiratory health of cystic fibrosis (CF) patients is acquisition of chronic Pseudomonas (P.) aeruginosa infections. The infection rate with P.
- Trial name
- NCT03905642
- Testing
- Arikayce™
- Where
- 11 sites in Belgium, Hungary and 5 more
- Volunteers
- 49 people
- Sponsor
- Insmed Incorporated
Pulmonary Disease, Chronic Obstructive
Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different Inhalers
The primary objective of this study is to evaluate the efficacy and safety of orally inhaled tiotropium and olodaterol as both a fixed dose combination and a free combination with respect to lung function and ECG parameters
- Trial name
- NCT02030535
- Testing
- olodaterol, tiotropium
- Where
- 6 sites in Germany
- Volunteers
- 53 people
- Sponsor
- Boehringer Ingelheim
Asthma (Diagnosis)
Beclometasone Dipropionate and Formoterol Inhalation Aerosol for Asthma
A multicenter, randomized, double-blind, active-controlled, parallel-group Phase III clinical study comparing the efficacy and safety of Beclometasone Dipropionate and Formoterol Inhalation Aerosol versus FOSTER® in patients with…
- Trial name
- NCT07768891
- Testing
- Beclometasone Dipropionate and Formoterol Inhalation Aerosol, FOSTER®
- Where
- China
- Volunteers
- 416 people
- Sponsor
- Lunan Better Pharmaceutical Co., LTD.
Cystic Fibrosis
A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)
This is a Phase 1/2 multicenter, open-label, single dose trial of SP-101 investigational gene therapy in adults with CF who are ineligible for or intolerant to CFTR modulator therapy.
- Trial name
- SAAVe (NCT06526923)
- Testing
- SP-101 and doxorubicin Cohort 1, SP-101 and doxorubicin Cohort 2
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Spirovant Sciences, Inc.
Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)
TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation
This is a Phase 1 pharmacokinetic (PK) study in healthy participants to assess the plasma pharmacokinetics, safety, and tolerability of a single inhaled dose of nezulcitinib (TD-0903) with supplemental oxygenation.
- Trial name
- NCT05091723
- Testing
- Nezulcitinib (TD-0903) Dose A, Nezulcitinib (TD-0903) Dose B
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Chronic Obstructive Pulmonary Disease
Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)
The objective of the REACT trial is to investigate the effect of roflumilast 500 μg tablets once daily versus placebo on exacerbation rate and pulmonary function in COPD patients who are concomitantly treated with a fixed…
- Trial name
- REACT (NCT01329029)
- Testing
- Roflumilast
- Where
- 180 sites in Australia, Austria and 19 more
- Volunteers
- 1,945 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Inhaled Insulin Compared to Metformin and Glimepiride in Type 2 Diabetes
This trial is conducted in Europe, Asia, North America and South America. The aim of this research trial is to compare the efficacy of inhaled insulin to glimepiride and metformin combination therapy in treatment of subjects with…
- Trial name
- iINHALE 7 (NCT00469586)
- Testing
- inhaled human insulin, metformin, glimepiride
- Where
- 59 sites in Argentina, Austria and 9 more
- Volunteers
- 174 people
- Sponsor
- Novo Nordisk A/S
Pulmonary Disease, Chronic Obstructive
Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease
Tolerability, efficacy and handling of Berodual® Respimat® 20/50µg/dose solution for inhalation in patients with chronic obstructive airways disease in daily practice
- Trial name
- NCT02231372
- Testing
- Berodual® Respimat® solution for inhalation
- Volunteers
- 4,602 people
- Sponsor
- Boehringer Ingelheim
Multiple Sclerosis (MS)
Avonex®: Safety, Blood Levels and Effects
The primary objective was to determine the tolerability of a new inhaled formulation of interferon beta-1a when given as a single dose, when given once per week for 4 weeks, and compared with standard intramuscular (IM) AVONEX®…
- Trial name
- C-851 (NCT01863069)
- Testing
- Interferon beta 1a, (IM) AVONEX®
- Where
- United Kingdom
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Trio Medicines Ltd.
COVID-19
The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection
Adults who have tested positive for SARS-CoV-2 infection and who may require supplemental oxygen will receive PUL-042 Inhalation Solution or placebo 3 times over a one week period in addition to their normal care.
- Trial name
- NCT04312997
- Testing
- PUL-042 Inhalation Solution
- Where
- 11 sites in United States
- Volunteers
- 101 people
- Sponsor
- Pulmotect, Inc.
Uncontrolled Asthma
Impact of GDMT in Uncontrolled Asthma Patients Receiving MHD Inhaled Corticosteroids + Long-acting β2 Agonist
The primary objective of this study is to evaluate whether GDMT can bring significant benefits to disease management in uncontrolled asthma patients receiving medium- to high-dose ICS-LABA.
- Trial name
- PRECISION (NCT07718724)
- Testing
- Intervention group
- Where
- 20 sites in China
- Volunteers
- 540 people
- Sponsor
- AstraZeneca
Obstructive Sleep Apnea
keePAP Device for Treatment of Obstructive Sleep Apnea
The aim of the study is to test the hypothesis that a new device would produce a significant decrease in obstructive breathing events during sleep as indexed by the Apnea Hyperpnoea Index (AHI) or Respiratory Disturbance Index…
- Trial name
- NCT01809418
- Testing
- keePAP
- Where
- Israel
- Volunteers
- 11 people
- Sponsor
- keepMED Ltd.
Bradycardia
Evaluation of the Performances of the Sleep Disordered Breathing Monitoring Function in Pacemaker
The IBSY04 clinical investigation is an European, prospective, multi-centre, non-randomized, longitudinal study.
- Trial name
- DREAM (NCT01537718)
- Testing
- REPLY 200
- Where
- 5 sites in France, Spain
- Volunteers
- 40 people
- Sponsor
- LivaNova
Healthy
Healthy Normal Volunteers Looking at Exposure and Effects of Multiple Doses of Technosphere® Insulin (TI) Using the Gen2C Inhaler
This is an open-Label, Randomized Study in Healthy Normal Volunteers looking at exposure and effects (PK/PD) of multiple doses of Technosphere® Insulin (TI) using the Gen2C inhaler.
- Trial name
- NCT01490762
- Testing
- Technosphere Insulin Inhalation Powder using the Gen2C inhaler, Regular Human Insulin
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Mannkind Corporation
Bioequivalence Study in Healthy Subjects
Pharmacokinetics and Bioequivalence Study of Budesonide Inhalation Aerosol in Humans
The test formulation of Budesonide Inhalation Aerosol is bioequivalent to the reference formulation in healthy Chinese subjects under fasting conditions.
- Trial name
- NCT06924190
- Testing
- Budiair® 200ug/puff inhalation aerosol, budesonide 200ug/puff inhalation aerosol
- Where
- 2 sites in China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Lunan Better Pharmaceutical Co., LTD.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.